Amneal Pharmaceuticals Launches Escitalopram Oxalate Oral Solution

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, LLC today announced the launch of Escitalopram Oxalate Oral Solution in 5 mg/5 mL strength, the first generic in liquid form on the market. Amneal’s product is a therapeutically equivalent alternative to Lexapro® (a registered trademark of Forest Laboratories, Inc.). Annual U.S. sales of Lexapro Oral Solution are $7.3 million according to December 2011 IMS Health market data.